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Oral prednisolone for acute otitis media in
children: protocol of a pilot randomised,
open-label, controlled study (OPAL study)
Respati W. Ranakusuma1,2* , Amanda R. McCullough1, Eka D. Safitri2, Yupitri Pitoyo2, Widyaningsih2,
Christopher B. Del Mar1 and Elaine M. Beller1
Abstract
Background: Acute otitis media (AOM) is an acute inflammation of the middle ear commonly found in children,
for which antibiotics are frequently prescribed. However, antibiotics are beneficial for only one third of AOM cases,
and then, with only modest benefit. Since antibiotic use leads to risk of side effects and resistance, effective
alternative treatments are required. Corticosteroids are a candidate because of their anti-inflammatory effects,
although evidence of their efficacy and harms is insufficient. Accordingly, we plan a large, rigorous clinical trial to
test this. Initially, we will test pre-specified methods and procedures (including the overall process, resources,
management, and scientific components) in a pilot study of corticosteroids for AOM, which will inform a future,
definitive trial.
Methods: This is a pilot pragmatic, randomised, open-label, single-blind, controlled study of corticosteroids as
either monotherapy or an addition to antibiotics in 60 children aged 6 months to 12 years with AOM in two cities
(Jakarta and Bekasi) in Indonesia. We will randomise eligible children to prednisolone or control. We will also stratify
by disease severity and randomise those with mild AOM to expectant observation plus prednisolone or observation
alone and those with severe AOM to prednisolone plus antibiotic or antibiotic alone. Our outcomes are to
determine (1) recruitment rates, (2) the success of the study procedures, (3) the ability to measure planned
outcomes of the proposed main study, (4) the compliance to study visits and study medication, and (5) verification
of the sample size calculation for the main study. We will also assess middle ear effusion using tympanometry as
part of a mechanistic sub-study.
Discussion: This study will test all procedures in preparation for the main study, including several potential
obstacles and challenges from the perspective of participating physicians, nurses, pharmacists, and the parents of
eligible children. This information will be useful for developing strategies to overcome practical and procedural
issues. This study may also provide information about the effects of corticosteroids on middle ear effusion in AOM.
Trial registration: Study registry number: ACTRN12618000049279. Name of registry: the Australian New Zealand
Clinical Trials Registry (ANZCTR). Date of registration: 16 January 2018.
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Background
Antibiotic resistance is a major global health threat,
which is mostly driven by antibiotic prescribing [1]. An-
tibiotics are commonly prescribed in primary care for
acute respiratory infections, including acute otitis media
[2–4]. Acute otitis media (AOM) is an inflammation of
the middle ear commonly found in children [5]. Ap-
proximately 75% of children experience AOM before the
age of five [6]. Recurrent AOM, defined as three or more
AOM episodes in the past 6 months or four or more
episodes in the past 12 months with at least one episode
in the past 6 months, occurs in 24% of American
children up to aged three [5, 7]. In Europe, 2% of
children under six have had three or more episodes of
AOM the previous year [6].
In the management of AOM, expectant observation
with pain management is commonly recommended for
children with mild AOM (e.g. mild ear pain, fever < 39 °C)
who can be reliably followed up [5]. Those with severe
symptoms, bilateral AOM in young age children, or with
perforated ear drums are more likely to benefit from
antibiotics [5, 8]. The option of using antibiotics must
be balanced against common adverse effects (e.g.
vomiting, diarrhoea, or rash) [9, 10]. In Australian
general practice, 89% of new AOM cases are managed
with antibiotics [11]. Similarly, in Indonesia, our survey
study demonstrated about 88% of physicians would
prescribe antibiotics for children with mild AOM.
Indonesian practice guidelines on the criteria for anti-
biotic use for AOM are vague [12, 13].
Alternative treatments have been proposed for treating
AOM, including herbal preparations, decongestants, and
corticosteroids [14–16]. However, the evidence for these
is too weak to be recommended in clinical practice. The
anti-inflammatory effect of corticosteroids suggests it
could be a viable treatment alternative for AOM [17].
Moreover, corticosteroids are effective additions to treat-
ment for other, more serious acute respiratory infections,
including pneumonia [18] and bacterial meningitis [19].
However, there is insufficient evidence of efficacy and
harms for AOM. A Cochrane review of randomised
controlled trials (RCTs) of corticosteroids for AOM (two
small studies; very low to low quality) indicated it might
be useful clinically, but the small sample size and wide
confidence intervals around the observed results leave
too much uncertainty [20]. An additional RCT of corti-
costeroids showed a reduction of the duration of ear dis-
charge in children with AOM and ventilation tubes [21].
Use of corticosteroids over a short duration is unlikely
to cause harm. A systematic review identified side effects
of short-course of corticosteroids (less than 2 weeks) in
children, such as gastrointestinal disturbances and some
behavioural changes. Due to diversity of corticosteroids’
types and duration in included studies, the results were
uncertain for both important beneficial and harmful ef-
fects of corticosteroids [22].
Accordingly, we plan to conduct an adequately pow-
ered clinical trial to address the uncertainties around the
effectiveness of corticosteroids for AOM in children.
Initially, we plan to conduct the pilot study described
here with an associated mechanistic sub-study using
tympanometry. The pilot study will test the feasibility of
characteristics of our main study design and all the study
procedures, as well as other operational strategies in our
proposed main study. As one of our outcomes is to
assess the ability to measure planned outcomes of the
proposed main study, we will also obtain the outcomes
and report these narratively. The mechanistic sub-study
will explore the potential mechanism of action of cortico-
steroids in the resolution of middle ear effusion in AOM.
Methods/design
Study aims and objectives
As this is a pilot study, we aim to test all pre-specified
methods and procedures that will be implemented in the
main study, including the overall process, resources, man-
agement, and scientific components, in a smaller size study.
The objectives for the pilot study are (1) to assess the
overall process and procedures of the main study (e.g.
the recruitment, randomisation, outcome measurement),
(2) to identify the experience and obstacles of physicians
and patients during the study, and (3) to verify the sam-
ple size calculation for the main study. The objective for
the mechanistic sub-study is to assess the mechanistic
effect of corticosteroids in improving middle ear effusion
in children with AOM using tympanometry.
Study design and setting
This is a pilot parallel, pragmatic, stratified, randomised,
open-label, single-blind, controlled study in an allocation
ratio of 1:1 (see Additional file 1. Protocol – Pilot OPAL
Study).
We are going to conduct this study in seven hospitals
in Jakarta and Bekasi: (1) Dr. Cipto Mangunkusumo
Hospital, (2) Persahabatan Hospital, (3) Gatot Subroto
Army Hospital, (4) Antam Medika Hospital, (5) Cempaka
Putih Islamic Hospital, (6) Proklamasi ENT Hospital, and
(7) Hermina Bekasi Hospital.
Participants
Inclusion criteria
We will include children aged 6 months to 12 years old
with AOM, defined as current onset (within 48 h) of
AOM-relevant symptoms (e.g. earache, ear tugging/rub-
bing or irritability in non-verbal children). Otoscopic
findings of acute inflammation (e.g. erythema) and mid-
dle ear effusion (e.g. bulged tympanic membrane, immo-
bile tympanic membrane, air fluid level) will confirm the
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diagnosis. Due to the pragmatic nature of this study, we
have chosen to reflect real practice, where physicians
often solely diagnose AOM based on symptoms alone
because of several limitations in visualising the ear
drums (e.g. non-cooperative children, narrow ear canals,
obstructing ear wax). Therefore, the otoscopic examin-
ation is not compulsory in diagnosing AOM. However,
prior to the study, we will emphasise the importance of
the use of otoscope in diagnosing AOM to the partici-
pating physicians and conduct training to visually iden-
tify clinical signs of AOM using otoscope.
Exclusion criteria
We will exclude children (1) with major and severe med-
ical conditions (e.g. heart diseases, kidney failure, tuber-
culosis), (2) who are immunocompromised (e.g. HIV, in
cancer treatment), (3) with congenital malformations
and/or syndromes (e.g. cleft palate, Down’s syndrome),
(4) who have high risk of strongyloidiasis infections, (5)
with ear ventilation tube(s), (6) who have been exposed
to persons with varicella (chicken pox) or active Zoster
infection in the past 3 weeks without prior varicella im-
munisation or infection, (7) who have taken systemic
(oral, injection) or topical steroids in the preceding
4 weeks, (8) who have taken antibiotics in the preceding
2 weeks, and (9) who are hypersensitive to prednisolone
or prednisone, or other corticosteroids.
Study intervention arm
Prednisolone tablets (Lupred®5) will be given at a dose of
1–2 mg/kg of body weight per day. As there is a wide
therapeutic dose window for prednisolone, this will enable
us to operationalise the dose as 10 mg/day for children
aged 6 months to up to 2 years; 20 mg/day for children
aged 2 up to 6 years; and 30 mg/day for children aged 6 to
12 years, simplifying both randomisation and dosage in-
structions. We determined the dose and duration of pred-
nisolone based on the paediatric otitis media studies and
other national and international practice guidelines of
inflammatory and infectious diseases in children (e.g. bron-
chial asthma, juvenile rheumatoid arthritis, acute bacterial
meningitis) [23–27]. An animal study [28] using mice
infected with common causative bacteria of AOM (Strepto-
coccus pneumoniae, non-typeable Haemophilus influenzae)
demonstrated that most AOM-related cytokines (e.g. inter-
leukin 1 alpha/IL-1α, tumour necrosis factor alpha/TNF-α)
peaked at 3 to 6 h, progressively reduced on day 4 to day 6,
and eventually were resolved after day 6. We will give the
prednisolone for 5 days to boost the natural resolution
process in middle ear inflammation and to minimise poten-
tial harms of corticosteroid use. A morning single daily
dose (6 to 8 am) is preferable over divided doses to prevent
the hypothalamic–pituitary–adrenal (HPA) axis suppres-
sion and for the convenience of the children and parents.
Due to the bitter taste of prednisolone despite the addition
of sweetener, we will advise the parents to mix the powder
with jam or sweet juice to make it more palatable for the
children.
We will stratify by disease severity and randomise
children with mild AOM to receive prednisolone plus
expectant observation, or expectant observation alone.
Those with severe AOM will be randomly allocated to
receive prednisolone plus antibiotic, or antibiotic alone.
Control arm
Budget constraints preclude us using matched placebo;
children allocated to control group will not receive
prednisolone but will receive standard care based on the
severity of their AOM (i.e. observation for mild AOM,
antibiotics for severe AOM).
Concurrent treatment
Prior to the randomisation, physicians may prescribe
symptomatic medications (e.g. antipyretic, analgesic,
decongestant) according to their usual practice. The
physicians will not prescribe systemic corticosteroids.
Therefore, the choice in prescribing these medications
will not be influenced by subsequent knowledge of
allocated treatment group.
Criteria for study drug discontinuation or modification
If children vomit less than 30 min after having a dose of
prednisolone, parents should give the same dose again.
However, if they vomit again after 30 min, parents
should not give another dose of prednisolone until the
next dose on the next day. If children keep vomiting
after receiving prednisolone, parents should contact the
research team. If the parents forget to give prednisolone
to their children, they can give the missed dose as soon
as they remember on the same day. To prevent this, we
developed several reminder strategies, such as daily
text-message reminders and a reminder note at the end
of the first 5 days in a daily symptom dairy. This will
remind the parents to give the study medication after
completing the symptom diary on that particular day.
If there are any adverse events and adverse drug reac-
tions which have been assessed by the research team that
would require the discontinuation of drug study and
further assessment and treatment, the treatment will be
discontinued for this particular case; however, follow-up
will continue, where possible.
Adherence monitoring
Participating physicians will provide information regard-
ing the administration of the prednisolone with the pre-
scription. One researcher will send daily text-message
reminders to all of the parents in both prednisolone and
control groups to (1) take the study medication regularly
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(during the intervention period of 5 days), (2) complete
the symptom diary daily until day 14 (2 weeks only), and
(3) visit the clinic for re-assessment at day 3 (visit 1),
day 7 (visit 2), day 30 (visit 3), and day 90 (visit 4). At
visit 1 and visit 2, the parents will return the first and
second mini booklets of symptom diary and the left-over
drug to the appointed nurse (at visit 2) for assessment of
adherence to study medication. We will visit the pa-
tients’ homes at day 14 to collect the last (the third) mini
booklet of symptom diary that will record the symptoms
from day 7 to day 14 after the baseline visit (see Add-
itional file 2. Case report forms – Pilot OPAL Study:
CRF06. Symptom diary).
For participants and parents who are no longer willing
to participate in the study (e.g. withdrawal from the
study, not taking the study medication), we will still
encourage them to come to their scheduled follow-up
visit. This will enable us to collect the outcome data for
those who are no longer in the study.
Outcomes
Our outcomes in this pilot study are to determine (1)
the recruitment rates, (2) the success of the study proce-
dures, (3) the ability to measure planned outcomes in
the main study, (4) the compliance to study visits and
study medication, and (5) the verification of sample size
calculation for the main study.
Recruitment rate is defined as the proportion of consul-
tations with potentially eligible children who provide their
consent to be included in the study. This is a crucial
aspect in a clinical trial. Low recruitment can result in a
discontinuation of an on-going study [29]. We will assess
this outcome at each month for the overall 6-month
recruitment duration of the pilot study.
We will assess the success of the study procedures by
identifying the process and obstacles during the following
procedures: (1) obtaining informed consent from the pa-
tients and their parents; (2) recruitment using prespecified
eligibility criteria and the use of otoscope to confirm
AOM if feasible; (3) stratification and randomisation, in-
cluding accessing the randomisation system and dispens-
ing the study medication; and (4) identification of AOM
symptoms and signs by clinical history taking and examin-
ation using otoscope and tympanometry. In AOM cases
with earwax, we will extract the earwax before performing
the otoscopy and tympanometry examination. If the ear-
wax extraction is not feasible (e.g. uncooperative patients,
cerumen prop), we will not include this patient in the
mechanistic sub-study, but we still include this patient in
the pilot study (as long as this patient fulfils the study cri-
teria). Patients with tympanic membrane perforation will
also not undergo tympanometry examination and will be
included in the pilot study only. We will assess this
outcome at the baseline visit (visit 0), day 3 (visit 1), day 7
(visit 2), day 30 (visit 3), and day 90 (visit 4).
We will identify the ability and challenges in measuring
planned outcomes in the main study from the perspectives
of participating physicians, nurses, and audiologists, as
well as the eligible children and their parents. For
example, we want to know whether it is difficult for the
physicians to identify the pain severity using visual
analogue scale (VAS) and acute otitis media severity of
symptoms scale (AOM-SOS), as these are not common
tools that are used in the management of AOM.
The compliance to study visits and study medication is
defined as a proportion of children who regularly take
the study medication according to the prespecified dose
and duration (assessed using the symptom diary and the
number of any left-over drug) and who come to
follow-up visits per protocol. Participants will be
followed closely by physicians and research staff. Chil-
dren will return for a visit at day 3 after randomisation
(visit 1), ensuring collection of the primary outcome.
The last outcome in this pilot study is to verify sample
size calculation for the main study. Based on our size
calculation, we must enrol 760 children with AOM. We
estimated that there will be 35% of the total sample of
children with AOM in the severe group (i.e. children
with severe symptoms, fever ≥ 39 °C, children aged
< 2 years with bilateral AOM, AOM with perforation
of tympanic membrane). Within this pilot study, we
will identify whether there will be a sufficient number of
children for our main study in each stratum and the
event rate in the control group.
We will also conduct a mechanistic sub-study using
tympanometry. As a primary outcome, we will assess the
change of middle ear effusion at similar time points with
the pilot study. We will measure middle ear effusion
using static acoustic admittance, defined as ‘the amount
of energy absorbed by the tympanic membrane and
middle ear, measured in millimetre ohm or millilitre’
[30]. The secondary outcomes are determining (1) the
duration of middle ear effusion and (2) the correlation
between ear pain and other symptoms (i.e. ear tugging,
irritability, crying, lack of sleep, lack of appetite, loss of
playfulness, fever) with the changes in middle ear effu-
sion at various time points.
Assessing the feasibility of measuring planned out-
comes in the main study (e.g. proportion of children
with pain at day 3, proportion of children with pain
and other non-specific AOM symptoms at various
time points, adverse effects, recurrence) will provide
the results for these outcomes. However, we will re-
port these narratively due to a limited sample size
and insufficient formal power calculation, which
makes us unable to detect actual effects of corticoste-
roids to improve clinical outcomes in AOM.
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Study procedure
Study site selection and training
In 2016, we tested feasibility of this study by surveying
physicians (general practitioners; ear, nose, throat spe-
cialists; and paediatricians) in three cities (DKI Jakarta,
Depok, Bekasi) in Indonesia, asking about current man-
agement of AOM in children, and their willingness to
participate in our proposed main study. We found there
were sufficient physicians who would prescribe cortico-
steroids for AOM among the 171 physicians from 87
primary/secondary to tertiary healthcare centres, in our
proposed study. For practical reasons, we will only in-
clude seven hospitals in Jakarta and Bekasi.
To ensure that all procedures and the outcome data
can be sufficiently conducted, collected, and recorded
properly according to prespecified plans, we will conduct
training for participating physicians prior to the imple-
mentation of the study. The training will include the
implementation of a clinical trial based on good clinical
practice guidelines, the summary of our study, and the
procedural steps in our study from the eligibility identifi-
cation, stratification, to data collection and management.
We will also provide training for nurses, pharmacists, and
tympanometry technicians in terms of the randomisation
process, dispensing and preparing the study medication,
and conducting and completing the outcome form for
tympanometry examination (see Additional file 3. Manual
of operations – Pilot OPAL Study and Additional file 4.
Training slides – Pilot OPAL Study).
Recruitment and stratification
In the main study, we will stratify eligible children by the
clinical specialty (primary care or secondary/tertiary health-
care centres) and severity of AOM (mild or severe). In this
pilot study, we will only include ear, nose, throat (ENT)
specialists who work in tertiary healthcare centres (see
Fig. 1). Therefore, we will stratify the eligible children only
based on their AOM severity. Children with mild AOM
symptoms and signs (e.g. mild ear pain, fever < 39 °C) will
be considered the mild AOM group, whilst those with
moderate to severe symptoms and signs (e.g. moderate to
severe ear pain, fever ≥ 39 °C, moderate to severe bulging
of tympanic membrane, children aged < 2 years with bilat-
eral AOM, AOM with perforated tympanic membrane,
complications) will be considered the severe AOM group.
We will then randomly allocate them to receive either
single dose prednisolone for 5 days as an addition to
expectant observation compared to observation alone
(mild AOM group) or as an addition to antibiotics com-
pared to antibiotic treatment alone (severe AOM group).
Randomisation and allocation concealment
All consenting children and their parents who are eli-
gible will be enrolled and stratified based on their AOM
severity by the participating physician. The eligibility
and stratification which is provided by the physicians
will help the appointed nurses to obtain the information
from the randomisation website, developed by Centre
for Research in Evidence-Based Practice (CREBP) Bond
University, Queensland, Australia. The randomisation
information for each subject is the intervention alloca-
tion and two-digit randomisation ID. A permuted block
randomisation sequence will be computer-generated,
prior to study commencement. The children will then
be randomly allocated to either prednisolone and ex-
pectant observation or expectant observation alone in
the mild group and either antibiotic with prednisolone
or antibiotic alone in the severe group.
During the consultation, the physician will prescribe
study medication for every study participant with the
dose based on age, and the nurse will give the prescrip-
tions to the participants who are allocated to the
intervention group (prednisolone group). Using the pre-
scription, the pharmacist will prepare the prednisolone
by crushing the tablets based on the prescribed dose,
mixing them with sweeteners, packing the mixed powder
in daily paper medication packs for 5 days. This medica-
tion preparation procedure is commonly implemented
for paediatric populations in Indonesia. The pharmacist
will then dispense the study medication along with in-
structions for preparation and record the dispensing on
the form provided by the study for this purpose. Batches
of study medication will be dispatched to participating
centres from a central pharmacy facility at the Clinical
Research Supporting Unit, Faculty of Medicine Universitas
Indonesia (CRSU FMUI).
Blinding
The appointed nurses, the study participants, and their
parents will know the allocation of the intervention. We
will ensure that the participating physicians and the au-
diologists/tympanometry technicians will be blinded to
the intervention allocation until all study outcomes, par-
ticularly pain, at day 3 (visit 1) are collected. At day 3,
study participants will meet the appointed nurses before
having a consultation with the physicians or undergoing
the tympanometry examination to ensure blinding of
outcome assessors. Emergency unblinding, before day 3,
can occur if there are serious adverse events (SAEs) and
only limited to the particular physician and patient who
is experiencing the SAE.
Follow-up timeline
We will measure the outcomes at various time points:
(1) visit 1 after 48-h observation (day 3), (2) visit 2 (day
7), (3) visit 3 (day 30), and (4) visit 4 (day 90). In the
main study, patients will visit the hospital at visit 1 and
visit 2, whilst the last two visits will be home visits.
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However, since the pilot study will be conducted simul-
taneously with the mechanistic sub-study, all the pa-
tients will have four hospital visits for tympanometry
examination. We will do a home visit at the second week
to collect the symptom diary (see Table 1).
Data collection
We will use a consent form, a recruitment log book,
case report forms (CRFs), and a symptom diary to meas-
ure and record all outcomes. The case report forms
consist of (1) eligibility form, (2) baseline information
form, (3) outcomes form, (4) randomisation form, (5)
study medication dispensing and return form, (6) feedback
form, and (7) serious adverse effects form.
We will identify the recruitment rate by assessing the
proportion of parents/children who provide their con-
sent divided by the proportion of consultations with
potentially eligible children during the study. We will
use a study recruitment log book to record the reason(s)
why children were not randomised.
We will assess the success of the study procedures
using a feedback form. Using the feedback form, physi-
cians, nurses, pharmacists, and the parents will rate their
understanding and challenges they encountered during
the implementation of study, including the completion
of the case report forms and the symptom diary, the
randomisation process, and dispensing and the preparing
of study medication. They will grade the severity of the
Fig. 1 Flow chart of the stratification and randomisation of the study
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challenges or obstacles on a scale with a range from very
easy to very difficult (see Additional file 2. Case report
forms—Pilot OPAL Study: CRF11. Feedback form).
To assess the ability to measure planned outcomes in
the main study, we will also use a feedback form to iden-
tify the understanding, the challenges, and the complex-
ity of the outcome assessment tools utilised for this
study (i.e. CRFs and patient symptom diary) from the
perspective of the study participants, their parents, and
the participating physicians (see Additional file 2. Case
report forms—Pilot OPAL Study: CRF05. Outcome form
and CRF06. Symptom diary). The CRFs and symptom
diary will record the clinical history and symptoms
(e.g. VAS, AOM-SOS), as well as physical examination
(e.g. temperature, blood pressure, otoscopic examination
if feasible). The VAS is acknowledged as a well-established
and validated scale for assessing pain [31]. It has a
100-mm horizontal scale with ‘no pain’ anchor at the left
and ‘the most severe pain’ at the right endpoint of the
scale. The scale will be determined by measuring the
distance from the left endpoint (‘no pain’) to the line
representing the pain level, marked by the parents or older
study participants (≥ 8 years old) [32]. A 10-mm difference
has been reported to indicate a clinically significant
change [33, 34]. The AOM–SOS is used to assess the
severity of other acute otitis media-relevant symptoms
daily and activity limitation due to acute otitis media in
the proceeding 12 to 24 h [35], particularly in non-verbal
children, using a scale of ‘no’, ‘a little’, and ‘a lot’. Shaikh et
al. [35] used the mean of 4.2 points as a minimal
Table 1 The schedule of enrolment, interventions, and assessments
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important difference. We have translated the original
(English) version of AOM–SOS to an Indonesian version
of AOM–SOS through forward and backward translation
process.
The compliance to the study and study medication will
be measured by assessing the completion of CRFs and
symptom diary, particularly the attendance of the study
participants and their parents to their scheduled
follow-up visits, the completion of the study medication
based on the symptom diary, and the left-over drug.
We will use the CRFs to assess the verification of
sample size calculation for the main study.
Data management
The integrity and completion of data will be maintained
through consistency checks during data entry and
cross-checks between items after data entry. All the ac-
tions and modifications to data stored in the database
will be documented and retrievable for viewing. Any
modification to original forms will be documented with
the date, name, and signature on paper and electronic
versions. Missing data or errors will be detected before
final submission to the electronic central database. This
central database will be checked regularly for its validity
and completeness of study data and will be protected
with a regular complete backup system.
Sample size
Even though our sample size calculation for our pro-
posed main study demonstrated that we need to recruit
760 children with AOM, we did not formally determine
the sample size for this pilot study. There are several
suggestions in calculating the sample size for a pilot
study (e.g. at least 55 participants or at least 9% of the
sample size of the main study) [36]. Since we will need
60 children for our mechanistic sub-study, we will also
include 60 children with AOM in our pilot study. The
sample size of the mechanistic sub-study was deter-
mined based on the main primary outcome, which is the
mean value of static acoustic admittance or acoustic
compliance in the tympanometry findings. In a previous
study of children with middle ear effusion who under-
went tympanometry assessment and had a history of
chronic or recurrent middle ear disease [37], the re-
sponse within each subject group was normally distrib-
uted with standard deviation 0.3. If the true difference in
the experimental and control means is 0.3 units, we will
need to study 22 experimental subjects and 22 control
subjects to be able to reject the null hypothesis that the
population means of the experimental and control
groups are equal with probability (power) 0.9. The type I
error probability associated with this test of this null
hypothesis is 0.05. With a 20% allowance for dropouts,
the total sample size becomes 56; consequently, we will
include 60 children for this pilot study.
We will recruit children with AOM from seven ter-
tiary healthcare centres that have tympanometry and are
located in eastern and central Jakarta. Our survey study
demonstrated that there were sufficient numbers of
potential paediatric AOM patients (97 children with
AOM in a week) and physicians (50 physicians) who
were willing to participate in the study at these hospitals,
meaning physicians see between 1 and 2 potentially
eligible patients/week. Using a worst-case scenario, we
assumed that only 30% of physicians would participate
and only 25% of patients would give consent to partici-
pate in our study, equating to a maximum of 29 children
per month. However, it is likely to take several weeks to
months for sites to recruit to optimum levels, so we have
allowed 6 months to recruit 60 children with AOM. The
study duration will be 9 months: 6 months for recruit-
ment plus 3 months for final follow-up data collection
(3 months post-enrolment).
In order to achieve adequate participant enrolment,
we will train nurses in each hospital on how to screen
all children with acute ear symptoms (e.g. ear pain, ear
tugging, ear discharge). We will ensure all study docu-
ments are accessible by providing binders of study re-
cruitment log book and case report forms at nursing
stations. In the first 2 weeks of the study (at least 3 days
per week), a researcher will also stand-by at the hospital
to help the nurses to identify and screen children with
suspected AOM.
Statistical methods
For the recruitment rate, we report the outcome as the
proportion of children in percentages. For the success of
the study procedures and the ability to measure planned
outcomes in the main study, we will report the out-
comes as the proportion of physicians in percentages
based on the grading scale of their feedback report on
prespecified outcome measure tools. For the compliance
to study visits and study medication, we will report the
outcomes as the proportion of children in percentages
who attend the follow-up visits and complete the cycle
of study medication.
To assess the verification of sample size calculation for
main study, we will report this outcome as the propor-
tion of children in each stratum (mild and severe acute
otitis media group) and those with pain at day 3 after
randomisation in the control group.
Although we will not formally report the clinical out-
comes due to a limited sample size and insufficient for-
mal power calculation of this pilot study, we will report
and analyse the clinical outcomes of the mechanistic
sub-study using tympanometry. We plan to analyse by
intention-to-treat; however, if there is loss to follow-up,
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we will not impute data, but use an available case ana-
lysis, due to the small sample size. We will still record
data on those who stop study medication, where possible,
and will include them in the analysis. For the mechanistic
sub-study, we will report continuous variables (i.e. the
change in middle ear effusion at various time points
(mean in day; standard deviation), the duration of middle
ear effusion, the difference between two groups) as a mean
difference with 95% confidence intervals (CI). We will
also report the correlation between ear pain and other
symptoms with the changes in middle ear effusion at
various time points.
Data monitoring
Since this is a short study, this pilot study does not
require a data monitoring committee. However, inde-
pendent personnel from Clinical Epidemiology and
Evidence-Based Medicine (CEEBM) Unit, Dr. Cipto
Mangunkusumo Hospital (CMH) – Faculty of Medicine
Universitas Indonesia (FMUI), who are not involved in
this study, will assess the process and the quality of patient
recruitment, data entry, and a compilation of research
data in the central database. Serious adverse event cases
will be identified, assessed, and managed by physicians.
These cases will then be recorded and reported to, as well
as be reviewed by the Medical Ethics Committee Faculty
of Medicine Universitas Indonesia (FMUI) (Indonesia)
and the Bond University’s Human Research Ethics Com-
mittee (BUHREC) (Australia).
Interim analysis
Due to the small number of recruited patients to the
study and because the duration of the study will be less
than 1 year, we will not conduct an interim analysis.
Harms
An adverse event is defined as any untoward medical
occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which does
not necessarily have to have a causal relationship with
study medication, whereas adverse effects or adverse
drug reactions are defined as all noxious and unintended
responses to a study medication related to any dose. Ad-
verse events and adverse drug reaction will be collected
after parents of the eligible children sign the written
consent and being enrolled in the study. All adverse
events occurring after the enrolment into the study, dur-
ing the additional treatment, or hospitalisation due to
adverse events and/or adverse drug reaction will be re-
corded. A subject who experiences serious adverse
events, defined as any untoward medical occurrence at
any dose that may result in-patient and/or prolonged
hospitalisation, persistent or significant disability, medic-
ally important events, life-threatening events, and death,
will receive sufficient treatment and will be recorded
and reported to the Medical Ethics Committee FMUI
and the BUHREC. We will not report serious adverse
events occurring after the study discontinuation, unless
there is a temporal relationship between study medica-
tions or other protocol procedure to the events, as well
as whether the event is unexpected or unexplained given
the subject’s clinical course, previous medical conditions,
and concomitant medications. All the serious adverse
events will be recorded in the serious adverse event
form.
Auditing
For the main study, we will establish an audit committee
from the CRSU FMUI and CEEBM Unit CMH-FMUI
which is independent from the study investigators. Ob-
servation and quality assessment of the study will be en-
sured to be always in accordance with the protocol and
International Conference Harmonization – Good Clin-
ical Practice (ICH-GCP) standards. However, we will not
conduct this in the pilot study because it is a short and
small size study.
Protocol amendments
Any modifications to the protocol which may impact on
the study process (e.g. modification of study objectives,
study design, study population, sample sizes, study pro-
cedures), potential benefits, and safety of the patients
will require a formal amendment to the protocol. This
amendment will be notified and approved by the Ethics
committee prior to its implementation. Notification will
also be sent to the health authorities in accordance with
local regulations. Minor modifications that may not im-
pact on the study process will only be notified to the
Ethics committee.
Confidentiality
All information related to the study will be securely stored
using password-protected access systems. These forms
will be kept confidential by only using coded patient IDs
as identifiers and will be stored separately from all forms
and records that contain names or other identifiers (e.g.
informed consent forms). All counselling sessions, includ-
ing general, ear-nose-throat, and tympanometry examina-
tions, will be conducted in private rooms. All the involved
research staff such as physicians, nurses, audiologists, and
pharmacists will be required to sign agreements to pre-
serve the confidentiality of all participants. The confidenti-
ality of every participant will be maintained and will not
be distributed externally without the written permission of
the participant, except for medical and research safety
purposes by national regulatory authorities if necessary.
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Access to data
The principal investigator will be given access to the
cleaned data sets. She will also have direct access to each
site’s data sets and by request. Project data sets will be
secured using passwords. To ensure confidentiality, data
dispersed to project team members will be blinded of
any identifying participant information.
Ancillary and post-study care
Short-term corticosteroids are very unlikely to have harm
outside those we will be measuring. However, we will ob-
serve any potential adverse effects from the study medica-
tion using a symptom diary. The symptom diary will
record adverse effects commonly found in corticosteroid
treatment (e.g. gastrointestinal disturbance, behavioural
changes), AOM complications (e.g. eardrums perforation,
mastoiditis), and also the severity of pain and other
non-specific symptoms of AOM. We will provide a 24-h
call centre for any emergency assistance and send regular
text reminders to the parents (for taking medication and
completing the diary), where parents will be able to report
any deteriorating or worsening symptoms of AOM. We
will also provide a list of healthcare providers to manage
emergency cases that might occur during the study. We
will be responsible for the adverse effects that will occur
from the study medication during and after the study re-
lated to study medication. The compensation will include
the treatment cost relevant with the study medication,
such as consultation visits, additional examinations, and
treatment (e.g. medicine, hospitalisation cost). Due to
other potential concurrent treatments within the study
medication, there will be robust review and analysis
process to conclude the cause of adverse events. Informa-
tion of management of adverse effects will be provided by
physicians during the process of consent approval before
entering the study. We will also include this information
in the patient symptom diary, including the 24-h emer-
gency call and list of recommended healthcare providers.
Dissemination policy
Study results, either statistically significant or non-significant,
will be reported in a journal manuscript after being distrib-
uted to all the investigators to be reviewed.
The authorships and contributions of this study will
be acknowledged on the protocol, manuscript, and the
report. Before the publication in medical journal or
paper presentation, the principal investigators will pro-
vide written consent of their acknowledgment and con-
tribution in the reported study.
Reproducible research
We will make the full protocol of this study to be publicly
available to maintain its transparency and reproducibility.
This full protocol will include detailed information regarding
the study, particularly on study design and conduct that not
are commonly included in the published protocol or infor-
mation description in clinical trial registry. We have regis-
tered the protocol at the Australian and New Zealand
clinical trial registry (https://www.anzctr.org.au/Trial/Regis
tration/TrialReview.aspx?ACTRN=12618000049279). We
will also publish the results of this study in relevant medical
journals as two separate papers as the following: (1) results
of the pilot study and (2) results of the mechanistic
sub-study. If necessary, we will include the anonymised
participant-level dataset in its appendix or online. Unpub-
lished outcomes will be reported in the full study report that
will be linked to the published study.
Discussion
By conducting this pilot study and mimicking all the
procedures in the main study, it enables us to identify
any practical or operational issues in performing the
main study (e.g. the recruitment and stratification
process, outcome measurement, randomisation process,
the compliance to the study). Our mechanistic sub-study
will demonstrate whether the potential mechanism of
action of corticosteroid will improve the resolution of
middle ear effusion in AOM cases and whether the
changes correlate with clinical symptoms of AOM.
We also presume that there are will be several chal-
lenges during the implementation of the main study,
particularly in these following processes: (1) data collec-
tion using otoscopes, as is not compulsory due to the
pragmatic design and the potential difficulties to visual-
ise the children’s tympanic membranes; (2) the stratifica-
tion and the management of AOM according to the
AOM severity, particularly for children in the mild
AOM group, due to unclear classification of AOM se-
verity and antibiotic treatment for AOM in Indonesia;
(3) clinical outcome measurement using the AOM
symptom reporting tools (e.g. VAS, AOM-SOS, symp-
tom diary) as this is still not practiced in the manage-
ment of AOM; and (4) the randomisation process using
a randomisation centre website to simplify the random-
isation allocation process. This will be a new and chal-
lenging experience for most of the participating nurses
who will run the randomisation.
We have identified several limitations in our study.
The first limitation is we will only include seven hospi-
tals in Jakarta and Bekasi, which will not represent the
coverage of the main study that will involve more than
50 primary/secondary and tertiary healthcare centres.
The second one is limited reliability of outcome assess-
ment instruments due to wide range of ages in this
study. The VAS has a limited reliability in self-report in
young children due to their lack of cognitive skills and
experience with scaling and estimating the magnitude.
The parents will assess the severity of the pain on
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children aged up to 8 years old [34], whilst the AOM–
SOS will also be used to assess the symptoms and activ-
ity limitation due to acute otitis media, which might be
better in younger children (< 2 years).
This pilot study is crucial to ensure the successful im-
plementation of the main study. The main study will
provide high-quality evidence about the value of cortico-
steroid in improving the resolution of AOM (e.g. pain
and other symptoms, middle ear effusion, recurrence). If
positive, it will provide an alternative to antibiotics for
children with mild symptoms, and a useful addition to
antibiotics in those with severe disease. If negative, it will
provide opportunity for researchers to test other poten-
tial alternatives for improving the clinical outcomes of
AOM.
By conducting this study, we will determine the import-
ance of (1) the identification of AOM severity in deter-
mining a sufficient, comprehensive, and evidence-based
management of AOM and (2) the use of symptom assess-
ment tools in the management AOM by introducing sev-
eral feasible validated tools. This can improve the quality
of the management of AOM, particularly in reducing the
use of antibiotics for mild AOM. As part of capacity build-
ing support for health practitioners (i.e. physicians, nurses,
audiologists, pharmacists) in Indonesia, this study will
provide opportunity for them to be directly involved in
clinical research and to develop their capacity for future
research.
Study status
We began recruitment on 22 February 2018. The proto-
col as described here was finalised on 17 October 2017.
Additional files
Additional file 1: Protocol—Pilot OPAL Study. This file is a protocol of a
pilot pragmatic, randomised, open-label, controlled study of an oral
prednisolone for acute otitis media in children. This file can be accessed
at https://pure.bond.edu.au/ws/portalfiles/portal/27513682/Additional_Fi-
le_1._Protocol_Pilot_OPAL_Study.pdf (PDF 491 kb)
Additional file 2: Case report forms—Pilot OPAL Study. This file
includes case report forms that are used in the pilot study: CRF01.
Participant information sheet and consent form; CRF02. Study registration
form; CRF03. Eligibility form; CRF04. Baseline information form; CRF05.
Outcome form; CRF06. Symptom diary; CRF07. Prescription of study
medication; CRF08. Randomisation form; CRF09. Follow-up visit card;
CRF10. Serious adverse events reporting form; CRF11. Feedback form;
FORM01. Study recruitment log book; FORM02. Study medication stock
book; FORM03. Study medication dispensing form; FORM04. Study
medication return form; FORM05. Completed case report form; FORM06.
Recapitulation of non-participating subject form; FORM07. Guideline of
antibiotics for acute otitis media; FORM08. Prednisolone dose for OPAL
study; FORM09. Instruction for using prednisolone for parents; FORM10.
Lupred pharmaceutical brochure. This file can be accessed at https://pure.bon-
d.edu.au/ws/portalfiles/portal/27513684/Additional_File_2._Case_report_form-
s_Pilot_OPAL_Study.pdf (PDF 4716 kb)
Additional file 3: Manual of operations—Pilot OPAL Study. This file
includes step-by-step manual for physicians, audiologists, nurses, and
pharmacists who participate in the study. The manual of operations
handbook was distributed during the trainings for participating
physicians, audiologists, nurses, and pharmacists. This file can be accessed
at https://pure.bond.edu.au/ws/portalfiles/portal/27513686/Additional_Fi-
le_3._Manual_of_Operations_Pilot_OPAL_Study.pdf (PDF 7905 kb)
Additional file 4: Training slides—Pilot OPAL Study. The training slide
was presented during the training for participating physicians,
audiologists, nurses, and pharmacists. The training was conducted prior
to the study commencement. This file can be accessed at https://
pure.bond.edu.au/ws/portalfiles/portal/27513688/
Additional_File_4._Training_Slides_Pilot_OPAL_Study.pdf (PDF 5528 kb)
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